Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 4Phase 1 4Phase 1/2 3

Status

Completed 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 28Lymphoma, Large B-Cell, Diffuse 21Lymphoma 16Multiple Myeloma 10Lymphoma, Non-Hodgkin 10Lymphoma, Follicular 8Lymphoma, B-Cell 7Neoplasms 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Burkitt Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Immunoblastic Lymphadenopathy 4Recurrence 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Primary Effusion 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, B-Cell, Marginal Zone 3Leukemia 3Waldenstrom Macroglobulinemia 2Plasmablastic Lymphoma 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Metastatic Castration-resistant Prostate Cancer 2Lymphoma, T-Cell 2Hematologic Neoplasms 2Enteropathy-Associated T-Cell Lymphoma 2

Interventions

Dexamethasone 33Cyclophosphamide 29venetoclax 18fludarabine 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × Prednisone × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT01166113 2023-06-29

PCP

Fondazione EMN Italy Onlus

Phase 1/2 Completed
67 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡